Calla Lily Clinical Care
London
About Calla Lily Clinical Care
Calla Lily Clinical Care is a women’s health focused B-Corp that has developed the proprietary Callavid® platform for intravaginal drug delivery. Initial target indications are in fertility and pregnancy, where the company seeks to offer the world’s first drug-device combo product to prevent miscarriages, and for IVF luteal phase support. Callavid® can also deliver live biotherapeutics (LBPs) to reduce recurrent Bacterial Vaginosis, cutting antibiotic usage and reducing the spread of antimicrobial resistance (AMR). Further use-cases include HRT for menopause use cases, and effective medical sample collection (Lilyvid™ device) to facilitate the next generation of biomarker-based diagnostic tests for endometriosis and a wide range of other conditions. The company’s devices are built upon underlying technology named a TIME Magazine Best Invention of the Year.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $5.4M
- Funding stage: Seed
- Last round: Grant (Apr 2025)
- Website: callali.ly
- Phone: [email protected]
Industries & Categories
Health Care, Health Diagnostics, Medical Device, Pharmaceutical, Women's
Social Profiles
Canonical: https://fsome.com/organization/calla-lily-clinical-care-87167 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.